Skip to main content
    V

    Volitionrx Ltd (VNRX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $0.19
    -0.04 (-15.26%)

    Market Cap: $8.30M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Volitionrx Ltd (VNRX) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Volitionrx (VNRX) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Volitionrx reported EPS of -$0.20, above the -$0.35 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -10.41%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.29
    Range-$0.37 - -$0.20
    7 analysts
    Revenue Consensus
    $696.15K
    Range$470.40K - $997.50K
    7 analysts

    Next Report

    VNRX has an expected report date of Mar 29, 2027.

    VNRX Earnings Call

    The latest VNRX earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, VNRX beat 20, missed 14 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $1.61M, up 156.7% from $627277 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.20-$0.35N/A+42.86%BeatN/A10 up, 0 downNov 12, 2026$1.61M
    Jun 30, 2026-$0.78-$0.68N/A-14.71%MissN/A10 up, 1 downAug 13, 2026$398657
    Mar 31, 2026-$0.97-$0.73-$0.80 - -$0.60-32.88%MissN/A31 up, 0 downMay 14, 2026$985076
    Dec 31, 2025-$0.05-$0.05N/A+2.78%BeatN/A50 up, 0 downMar 31, 2026$447034
    Sep 30, 2025-$1.06-$1.04-$1.40 - -$0.80-1.92%MissN/A50 up, 2 downNov 13, 2025$627277
    Jun 30, 2025-$1.31-$1.00-$1.20 - -$0.80-31.00%MissN/A60 up, 1 downAug 14, 2025$406688
    Mar 31, 2025-$0.06-$0.06-$0.06 - -$0.020.00%In lineN/A41 up, 0 downMay 15, 2025$246385
    Dec 31, 2024-$1.20-$1.07-$1.20 - -$0.80-12.15%MissN/A30 up, 0 downMar 31, 2025$194595
    Sep 30, 2024-$1.40-$1.30-$1.60 - -$1.00-7.69%MissN/A52 up, 0 downNov 14, 2024$474522
    Jun 30, 2024-$1.60-$1.85-$2.20 - -$1.80+13.51%BeatN/A40 up, 0 downAug 14, 2024$395797
    Mar 31, 2024-$2.00-$2.15-$2.40 - -$2.00+6.98%BeatN/A40 up, 0 downMay 13, 2024$168597
    Dec 31, 2023-$0.11-$0.11-$0.11 - -$0.100.00%In lineN/A30 up, 0 downMar 26, 2024$243973
    Sep 30, 2023-$2.14-$2.47-$3.00 - -$2.40+13.36%BeatN/A50 up, 0 downNov 14, 2023$165211
    Jun 30, 2023-$2.80-$2.87-$3.20 - -$2.60+2.44%BeatN/A40 up, 0 downAug 15, 2023$216310
    Mar 31, 2023-$3.00-$2.70-$3.00 - -$2.60-11.11%MissN/A30 up, 0 downMay 11, 2023$149808
    Dec 31, 2022-$0.13-$0.15-$0.15 - -$0.14+13.33%BeatN/A50 up, 0 downMar 15, 2023$119715
    Sep 30, 2022-$2.80-$2.93-$3.20 - -$2.80+4.44%BeatN/A50 up, 0 downNov 14, 2022$32714
    Jun 30, 2022-$2.80-$2.87N/A+2.44%BeatN/AN/A0 up, 0 downAug 10, 2022$39752
    Mar 31, 2022-$2.80$0.90-$0.80 - $1.00-411.11%MissN/A40 up, 0 downMay 11, 2022$114211
    Dec 31, 2021-$0.15-$0.14-$0.15 - -$0.11-7.14%MissN/A4N/AMar 30, 2022$14240
    Sep 30, 2021-$2.60-$2.07-$2.60 - -$2.00-25.60%MissN/A5N/ANov 10, 2021$25483
    Jun 30, 2021-$2.08-$2.33-$2.60 - -$2.00+10.73%BeatN/A5N/AAug 11, 2021$24782
    Mar 31, 2021-$2.40-$2.27-$2.40 - -$2.20-5.73%MissN/A3N/AMay 11, 2021$25530
    Dec 31, 2020-$0.11-$0.10-$0.10 - -$0.10-10.00%MissN/A3N/AMar 22, 2021$20553
    Sep 30, 2020-$1.93-$2.20-$2.40 - -$2.20+12.27%BeatN/A4N/ANov 12, 2020$575
    Jun 30, 2020-$2.36-$2.45-$3.00 - -$2.00+3.67%BeatN/A5N/AAug 13, 2020$5194
    Mar 31, 2020-$2.80-$1.93N/A-45.08%MissN/A2N/AMay 7, 2020$544
    Dec 31, 2019-$1.60-$2.20-$2.20 - -$2.00+27.27%BeatN/A2N/AFeb 20, 2020N/A
    Sep 30, 2019-$2.00-$2.10-$2.20 - -$2.00+4.76%BeatN/A3N/ANov 12, 2019$17096
    Jun 30, 2019-$2.20-$2.27-$2.40 - -$2.20+3.08%BeatN/A4N/AAug 12, 2019N/A
    Mar 31, 2019-$2.40-$2.40-$2.60 - -$2.200.00%In lineN/A3N/AMay 8, 2019N/A
    Dec 31, 2018-$0.11-$0.13-$0.15 - -$0.12+15.38%BeatN/A3N/AMar 13, 2019N/A
    Sep 30, 2018-$2.80-$2.80-$3.20 - -$2.600.00%In lineN/A3N/ANov 7, 2018N/A
    Jun 30, 2018-$3.00-$3.00-$3.20 - -$2.600.00%In lineN/A4N/AAug 13, 2018N/A
    Mar 31, 2018-$3.40-$3.20-$3.20 - -$3.20-6.25%MissN/A1N/AMay 10, 2018N/A
    Dec 31, 2017-$0.15-$0.16-$0.17 - -$0.15+6.25%BeatN/A3N/AMar 1, 2018N/A
    Sep 30, 2017-$3.00-$3.00N/A0.00%In lineN/AN/AN/ANov 9, 2017N/A
    Jun 30, 2017-$2.60-$2.80N/A+7.14%BeatN/AN/AN/AAug 9, 2017N/A
    Mar 31, 2017-$2.60-$2.75N/A+5.45%BeatN/AN/AN/AMay 11, 2017N/A
    Dec 31, 2016-$0.12-$0.13N/A+7.69%BeatN/AN/AN/AMar 10, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.48, after -$6.20 the year before. It was -$8.32 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.48N/A
    Dec 31, 2024-$6.20N/A
    Dec 31, 2023-$8.05N/A
    Dec 31, 2022-$8.53N/A
    Dec 31, 2021-$7.23N/A
    Dec 31, 2020-$7.20N/A
    Dec 31, 2019-$8.20N/A
    Dec 31, 2018-$9.31N/A
    Dec 31, 2017-$8.35N/A
    Dec 31, 2016-$8.32N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,700 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20265,6999
    2025Q4Dec 31, 20256,41710
    2025Q3Sep 30, 20256,0369
    2025Q2Jun 30, 20256,2499
    2025Q1Mar 31, 20254,6706
    2024Q3Sep 30, 20247,94310
    2024Q2Jun 30, 20244,62311

    2026Q1 Earnings Call

    Opening remarks

    Louise Batchelor Day Group Chief Marketing and Communications Officer Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. Terig Hughes, Group Chief Financial Officer, will open the call providing a financial report before handing over to Cameron Reynolds, Group Chief Executive Officer, who will provide a summary of recent key achievements and upcoming milestones. We will then open the conference call to a question-and-answer session. And with that, I'll turn the call over to Terig.

    Terig Hughes Group Chief Financial Officer Thanks very much, Lou, and hello, everyone. I'm delighted to provide a financial report for the first quarter ending 31st of March 2026. From a revenue perspective, we recorded approximately $1 million in the first quarter compared to approximately $0.2 million in the same period of 2025. This increase was primarily driven by a $0.7 million increase in deferred revenue recognition related to our Nu.Q Vet agreement with Heska, the result of a periodic review and consistent with our accounting policies. As we have stated previously, at this stage of commercialization, revenues remain fairly lumpy and difficult to predict from one quarter to the next. And so while we remain confident of continuing to see solid growth year-over-year, we will not be providing revenue guidance for 2026 at this point in time. From an expenditure perspective, the operating expenses for the quarter were $6.3 million compared to $5.8 million in the same period last year. This increase partly reflected severance costs related to cost reduction actions, which will result in future savings as well as higher R&D costs related to work on our Capture-Seq and completion of certain lung cancer studies. As we reported in the recent 10-K, looking at the trend over the last two years, we now operate at significantly lower levels of expenditure.

    Frequently Asked Questions About VNRX

    When is Volitionrx's next earnings date?

    Volitionrx's next earnings report is expected for Mar 29, 2027.

    Did VNRX beat earnings estimates last quarter?

    Yes. Volitionrx reported EPS of -$0.20 for the quarter ended Sep 30, 2026, above the -$0.35 estimate, a 42.86% surprise.

    What EPS do analysts expect from VNRX next quarter?

    The consensus EPS estimate for Volitionrx for the quarter ending Dec 31, 2026 is -$0.29 from 7 analysts, with estimates from -$0.37 to -$0.20.

    How often does VNRX beat earnings estimates?

    Volitionrx beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -5.88%.